PatientsVille.com LogoPatientsVille.com

Severe Stroke With Affected Arm Motor Function | RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke

Severe Stroke With Affected Arm Motor Function research study

What is the primary objective of this study?

Stroke patients who have little or no voluntary movement in the hand on the more affected side of their body more than one year after stroke have few treatment options. This project proposes to test the efficacy of a form of Constraint-Induced Movement therapy designed for patients with such severe impairment in conjunction with an agent, fluoxetine, which has been shown in some studies to enhance brain neuroplasticity in response to training. Constraint-Induced Movement therapy, which is abbreviated CIMT, is a form of physical rehabilitation based on basic research in neuroscience and behavioral science. If the project is successful, an efficacious, evidence-based therapy will become available to stroke patients for what is now a largely untreated condition

Who is eligible to participate?

Inclusion Criteria: - Motor criteria determinations will be made with the subject sitting. The more-affected forearm will be resting on a supporting surface (e.g., arm of a chair) to allow for maximum wrist flexion with gravity. - The minimum motor criterion (MMC) for inclusion in Grade 5 (severe impairment) will be ability to: - initiate extension against gravity at the wrist or at least one digit, - initiate extension and flexion at the elbow, - actively move the shoulder ≥ 30° in flexion, abduction, or scaption - The MMC for inclusion in Grade 4 (moderately severe impairment) will be ability to actively: - extend at least two fingers more than 0° but less than < 10°, - extend or abduct thumb ≥ 10° - extend wrist ≥ 10° from a fully flexed starting position, - extend elbow ≥ 20° from a 90° flexed starting position, - flex and abduct shoulder > 45°. - Stroke patients who can extend at least two fingers ≥ 10° at the metacarpophalangeal (MCP) joint and either the proximal or distal interphalangeal (PIP or DIP) joint will be excluded. - Additional inclusion criteria are: - must score ≤ 4 on the Modified Ashworth Scale (23)116 for all more-affected arm joints - meet the following passive range of movement criteria: - ≥ 90° shoulder flexion, - ≥ 90° shoulder abduction, - ≥ 45° shoulder external rotation, - ≤ 30° short of normal elbow extension, forearm supination to at least neutral, - forearm pronation 45° or more from neutral, - ≤ 35° short of normal wrist extension, - ≤ 35° short of normal MCP extension on all the digits. Exclusion Criteria: - Less than 1 year post-stroke. - Frailty or insufficient stamina to carry out the requirements of the therapy (based on clinical judgment). - Ferrous metal in body or medical complications or psychological problems that would prohibit receiving an MRI. - Positive pregnancy test for women of child-bearing age since 3T MRI is contraindicated for pregnant women. - Other neurological or musculoskeletal conditions affecting UE function. - Medication will not be exclusionary except in the following cases: a. participation in any experimental drug study, b. Botox injections to the more-affected UE < 3 months prior to enrollment, c. Baclofen or Dantrium taken orally at the time of study, d. fluoxetine or other antidepressant with SSRI-like properties taken < 3 months prior to enrollment, e. any agents that would contraindicate concurrent fluoxetine. If subjects are on other medications, the medications will be recorded and the possible effect on treatment outcome will be analyzed separately. - Moderate or greater depressive symptoms as indicated by a score > 30/63 on the Beck Depression Inventory (24,25).117, 118 - Concurrent participation in any formal physical rehabilitation program or clinical trial. - Excessive pain in any joint of the more-affected arm that could limit ability to cooperate with the intervention (based on clinical judgment). - Serious cognitive deficits manifested by a Folstein Mini-Mental State Examination (MMSE) score ≤ 24 (26).119 - Inadequate ability to follow test instructions as indicated by a Token Test of the Multilingual Aphasia Examination score ≤ 36 (27).120 - Serious, uncontrolled medical problems as judged by the Medical Director (e.g., severe rheumatoid arthritis, serious joint deformity of arthritic origin, symptomatic cancer or renal disease, any end-stage pulmonary or cardiovascular disease, senility or a deteriorated condition due to age, uncontrolled epilepsy). - Motor problems that are not primarily unilateral. - Poor motivation to participate in the study (if a person is only marginally interested, he/she is a bad risk as a subject). - Less than 40 years old. - Previous CIMT.

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Severe Stroke With Affected Arm Motor Function

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Fluoxetine

Drug:Placebo

Procedure:eCMIT

Procedure:Usual Care

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

eCMIT and Fluoxetineexpanded form of Constraint Induced Movement Therapy (eCIMT) combined with Fluoxetine (FLX)

eCIMT and placeboexpanded form of Constraint Induced Movement Therapy (eCIMT) combined with placebo

Usual care and fluoxetineUsusal physical care combined with Fluoxetine (FLX)

Usual care and placeboUsual physical care combined with placebo

Study Status

Withdrawn

Start Date: November 2016

Completed Date: November 2021

Phase: Phase 2

Type: Interventional

Design:

Primary Outcome: Grade 4/5 Motor Activity Log (MAL) Arm Use Scale

Secondary Outcome: Grade 4/5 MAL Arm Use scale

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: University of Alabama at Birmingham

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01963832

Discuss Prozac